Several weeks ago, Cathie Wood's ARK Fund ARKG invested in the biotech psychedelics sector, specifically in major player Atai Life Sciences ATAI.
The first purchase took place in February 2022, when ARK bought 83,278 shares of Atai Life Sciences. Less than two weeks later, the company acquired four times that, bringing its total ownership to over 340,000 shares, as first reported by Jason Najum on Microdose.
In early July 2022, the company’s spreadsheet showed it held a total 1,827,047 of Atai’s shares -representing an increase of more than 138,000 shares from March 2022.
Photo Courtesy of Jeffrey Blum on Unsplash.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Earn global recognition for your achievements.
- Shine a spotlight on the people around you that deserve their moment.
- Celebrate with the newest, hottest and most successful in the cannabis industry.
Join us on September 27-28, 2023 at Chicago Marriott Downtown Magnificent Mile in Chicago, IL.